ATE243713T1 - Antiidiotypischer antikörper, der ein immunantwort gegen ein glykosphingolipid induziert und seine verwendung - Google Patents
Antiidiotypischer antikörper, der ein immunantwort gegen ein glykosphingolipid induziert und seine verwendungInfo
- Publication number
- ATE243713T1 ATE243713T1 AT98108374T AT98108374T ATE243713T1 AT E243713 T1 ATE243713 T1 AT E243713T1 AT 98108374 T AT98108374 T AT 98108374T AT 98108374 T AT98108374 T AT 98108374T AT E243713 T1 ATE243713 T1 AT E243713T1
- Authority
- AT
- Austria
- Prior art keywords
- immune response
- response against
- induces
- glycosphingolipide
- antiidiotypic antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35703789A | 1989-05-25 | 1989-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE243713T1 true ATE243713T1 (de) | 2003-07-15 |
Family
ID=23404043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90909554T ATE174799T1 (de) | 1989-05-25 | 1990-05-25 | Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung |
| AT98108374T ATE243713T1 (de) | 1989-05-25 | 1990-05-25 | Antiidiotypischer antikörper, der ein immunantwort gegen ein glykosphingolipid induziert und seine verwendung |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90909554T ATE174799T1 (de) | 1989-05-25 | 1990-05-25 | Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5529922A (de) |
| EP (3) | EP0884329B1 (de) |
| JP (1) | JP3392860B2 (de) |
| AT (2) | ATE174799T1 (de) |
| CA (1) | CA2057010C (de) |
| DE (3) | DE473721T1 (de) |
| DK (2) | DK0473721T3 (de) |
| ES (2) | ES2207768T3 (de) |
| WO (1) | WO1990014104A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6805862B1 (en) | 1989-05-25 | 2004-10-19 | Sloan-Kattering Institute For Cancer Research | Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof |
| US6432402B1 (en) | 1989-05-25 | 2002-08-13 | Sloan-Kettering Institute For Cancer Research | Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof |
| US5268454A (en) * | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
| US20030035797A1 (en) * | 1992-01-27 | 2003-02-20 | Sloan-Kettering Institute For Cancer Research | Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof |
| US5874085A (en) * | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
| US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
| CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
| US5612030A (en) * | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| US5935821A (en) * | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
| US5792455A (en) * | 1996-03-21 | 1998-08-11 | Sloan-Kettering Institute For Cancer Research | Anti-idiotypic antibody vaccines |
| US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
| EP1071700B1 (de) * | 1998-04-20 | 2010-02-17 | GlycArt Biotechnology AG | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| US6989276B2 (en) | 2001-05-10 | 2006-01-24 | Battelle Energy Alliance, Llc | Rapid classification of biological components |
| USRE46351E1 (en) | 2001-05-10 | 2017-03-28 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| WO2007048092A2 (en) * | 2005-10-17 | 2007-04-26 | Spidertech, A Division Of Stoecker & Associates, A Subsidiary Of The Dermatology Center, Llc | Immunoassay for venom detection including noninvasive sample collection |
| US20080286881A1 (en) * | 2007-05-14 | 2008-11-20 | Apel William A | Compositions and methods for combining report antibodies |
| WO2011022103A2 (en) * | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | Ganglioside epitopes for treating guillain-barre syndrome |
| US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| US8969009B2 (en) * | 2009-09-17 | 2015-03-03 | Vicki S. Thompson | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE32833E (en) * | 1982-03-01 | 1989-01-17 | President And Fellows Of Harvard College | Screening vaccines and immunization process |
| EP0134868A1 (de) * | 1983-08-26 | 1985-03-27 | Anda Biologicals | Glutaraldehyd-aktivierte einzellige Organismen als feste Träger für Sensibilisierungsmittel und Gebrauch von sensibilisierten einzelligen Organismen |
| US4918164A (en) * | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
| US5614610A (en) * | 1984-12-21 | 1997-03-25 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
| AU603585B2 (en) * | 1986-05-07 | 1990-11-22 | Sloan-Kettering Institute For Cancer Research | Vaccine for stimulating or enhancing production of antibodies directed against GM2 |
| US4849509A (en) * | 1987-02-20 | 1989-07-18 | The Wistar Institute | Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies |
| IT1217314B (it) * | 1987-02-20 | 1990-03-22 | Sclavo Spa | Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale |
| AU1711888A (en) * | 1987-04-24 | 1988-12-02 | Biogen, Inc. | Immunotherapeutic methods and compositions |
| US4900547A (en) * | 1987-10-23 | 1990-02-13 | University Of British Columbia | Method to immunize mammals against tumors |
-
1990
- 1990-05-25 CA CA002057010A patent/CA2057010C/en not_active Expired - Fee Related
- 1990-05-25 JP JP50899290A patent/JP3392860B2/ja not_active Expired - Fee Related
- 1990-05-25 ES ES98108374T patent/ES2207768T3/es not_active Expired - Lifetime
- 1990-05-25 AT AT90909554T patent/ATE174799T1/de not_active IP Right Cessation
- 1990-05-25 EP EP98108374A patent/EP0884329B1/de not_active Expired - Lifetime
- 1990-05-25 DK DK90909554T patent/DK0473721T3/da active
- 1990-05-25 EP EP90909554A patent/EP0473721B1/de not_active Expired - Lifetime
- 1990-05-25 DE DE199090909554T patent/DE473721T1/de active Pending
- 1990-05-25 DK DK98108374T patent/DK0884329T3/da active
- 1990-05-25 EP EP03004225A patent/EP1334984A1/de not_active Withdrawn
- 1990-05-25 DE DE69034087T patent/DE69034087T2/de not_active Expired - Fee Related
- 1990-05-25 AT AT98108374T patent/ATE243713T1/de not_active IP Right Cessation
- 1990-05-25 WO PCT/US1990/003061 patent/WO1990014104A1/en not_active Ceased
- 1990-05-25 ES ES90909554T patent/ES2127186T3/es not_active Expired - Lifetime
- 1990-05-25 DE DE69032855T patent/DE69032855T2/de not_active Expired - Fee Related
-
1995
- 1995-05-22 US US08/445,906 patent/US5529922A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1334984A1 (de) | 2003-08-13 |
| ES2207768T3 (es) | 2004-06-01 |
| EP0473721A4 (de) | 1994-03-23 |
| DE69032855T2 (de) | 1999-08-12 |
| EP0884329B1 (de) | 2003-06-25 |
| JP3392860B2 (ja) | 2003-03-31 |
| DE69034087D1 (de) | 2003-07-31 |
| CA2057010A1 (en) | 1990-11-26 |
| EP0473721A1 (de) | 1992-03-11 |
| DK0884329T3 (da) | 2003-10-20 |
| CA2057010C (en) | 2002-08-06 |
| HK1014658A1 (en) | 1999-09-30 |
| US5529922A (en) | 1996-06-25 |
| DE69032855D1 (de) | 1999-02-04 |
| DK0473721T3 (da) | 1999-08-23 |
| EP0884329A1 (de) | 1998-12-16 |
| WO1990014104A1 (en) | 1990-11-29 |
| JPH05500600A (ja) | 1993-02-12 |
| EP0473721B1 (de) | 1998-12-23 |
| ATE174799T1 (de) | 1999-01-15 |
| ES2127186T3 (es) | 1999-04-16 |
| DE473721T1 (de) | 1993-04-29 |
| DE69034087T2 (de) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE243713T1 (de) | Antiidiotypischer antikörper, der ein immunantwort gegen ein glykosphingolipid induziert und seine verwendung | |
| FI941572A7 (fi) | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä | |
| DE69029015D1 (de) | Antikörper gegen menschlichen Interleukin-6-Rezeptor | |
| IT1138367B (it) | Anello smorzatore di vibrazioni | |
| DE69530415D1 (de) | Rekombinierte sequenzen des monoklonalen anti-idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind | |
| BR9106392A (pt) | Anticorpos anti-icam-1 enxertados-cdr humanizados,metodos de preparacao e uso dos mesmos | |
| IT8020166A0 (it) | Procedimento e dispositivo per fissare pastiglie d'usura ad attrito. | |
| DE69010669D1 (de) | Reibbelag und belagträgerscheibe. | |
| DE3788148D1 (de) | Monoklonale Antikörper und deren Verwendung. | |
| IT1207589B (it) | Composizione di anticorpi monoclonali umani cross-protettivi. | |
| ITRM920457A0 (it) | Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteinaumana. | |
| FI910572A0 (fi) | Regnmaetare med anordning som paovisar tilltaeppning. | |
| ITRM910842A1 (it) | Collaudo elettromagnetico di funi metalliche. | |
| IT8249377A0 (it) | Fermaglio perfezionato per articolidi gioielleria e simili | |
| FI920565A0 (fi) | Ige-receptor antikroppar. | |
| IT1226729B (it) | Dispositivo di fissaggio per il cinturino di sostegno di un ombrello. | |
| DK717888D0 (da) | Monoklonale antistoffer | |
| FI943524A7 (fi) | Hepatiitti C -viruksen vastaisia monoklonaalisia vasta-aineita ja anti -idiotyyppisiä vasta-aineita | |
| MX9202642A (es) | Anticuerpos monoclonales y antigeno para melanoma humano. | |
| DE3851855D1 (de) | Gegen die Gamma-Kette des T-Zell-Rezeptors gerichteter monoklonaler Antikörper. | |
| IL100771A0 (en) | Compositions of antibodies directed towards the human or animal interleukin-2 receptor | |
| NO912509L (no) | Fremgangsmaate for fremstilling av substituerte acykliske nukleosider og mellomprodukter derav. | |
| IT9021862A0 (it) | Vaglio per la classificazione di materiali di diverso peso specifico | |
| IT1244379B (it) | Dispositivo smorzatore per la protezione sismica di costruzioni, qualiviadotti e simili | |
| DE3787416D1 (de) | Monoklonaler Antikörper gegen Laforakörper. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0884329 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |